Bulk Drug Rules Tightened for Pharmacies

Summary#

HB 917 would amend and reenact parts of Virginia’s Code of Virginia on pharmacy records and compounding. The bill’s stated subject is the use of bulk drug substances and recordkeeping; the supplied text does not set out a separate goal. The bill is at the introduced stage and is not law.

  • Pharmacists may use bulk drug substances only if the substances meet listed FDA or United States Pharmacopeia conditions and additional requirements for quality, testing, manufacturing, and distribution.
  • Pharmacies would have to keep specified records for compounded products, including information on ingredients, quality testing, and staff training. The Board of Pharmacy could request records, which must be available within 48 hours or another reasonable time set by the Board.
  • The Board could send certain inspection or investigation information about possible federal violations to the U.S. Secretary of Health and Human Services, with an exception for compounding for office-based administration. It could also share disciplinary and inspection records with the National Association of Boards of Pharmacy.
  • The text includes restrictions on compounding certain unsafe or investigational drugs and on making drugs that are essentially copies of commercially available products. Because the current Code is not supplied, it is not clear how much of these provisions would change current law.
  • The Board would have to adopt regulations to implement the act, with public comment before adoption. Its initial regulations would be exempt from the usual Administrative Process Act requirements.

What it means for you#

  • Pharmacists and pharmacies: If the bill becomes law, the text would set conditions for using bulk drug substances. These include a valid certificate of analysis, quality-control testing, and evidence that the manufacturing facility is FDA-registered and had a qualifying FDA inspection within the last two years. The substance must also come through a licensed distributor or an approved supplier, subject to the bill’s stated conditions.
  • Pharmacies that compound: The text requires records and a written quality-assurance plan covering matters such as staff training, competence checks, environmental controls, and equipment calibration. It does not say how much this would add to existing requirements.
  • The Board of Pharmacy: It could request compounding records and share specified records with federal authorities and the National Association of Boards of Pharmacy. The bill does not create a new independent agency.
  • Patients and prescribers: The bill does not directly change who may receive a prescription, create a new patient benefit, or require a pharmacy to compound a drug.

Money#

No cost estimate is included in the supplied material.

  • Pharmacies could face costs for records, testing, quality assurance, and documenting the source and quality of bulk substances. The bill does not estimate those costs, and the supplied text does not show which requirements are new.
  • The bill requires the Board to adopt initial regulations but gives no staffing or cost estimate.
  • The bill does not set a tax, fee, fine, or appropriation.

What is unclear#

  • The current Code of Virginia is not supplied, so it is not possible to verify which requirements are new and which may already be law.
  • The text does not set a start date or explain when pharmacies must meet the requirements.
  • Terms such as “pharmaceutical grade,” “inordinate amounts,” and “reasonable means” are not fully defined in the bill. The Board may add some requirements by regulation.
  • The bill does not explain how the Board would handle requests for records beyond the stated response time, or what review or appeal process would apply.
  • The full effect of the exception for compounding for office-based administration is unclear from the supplied text.

Case for#

  • A possible argument for the bill is that requiring certificates, testing, and information about manufacturing and impurities could help pharmacists check the quality and source of bulk drug substances.
  • More detailed records could make it easier for the Board to inspect compounding practices and assess whether pharmacies follow required procedures.
  • Sharing specified information with federal authorities and pharmacy boards could help regulators address possible violations across jurisdictions.

Case against#

  • The bill’s requirements could add costs and paperwork for pharmacies, but the materials do not estimate the burden or explain how it compares with current rules.
  • Some key standards are left open to interpretation or later regulation, which could make it hard for pharmacies to know what will qualify.
  • The bill allows information sharing with outside bodies but does not explain what safeguards, notice, or correction process would apply to the information.
  • Because the current law is not supplied, readers cannot tell whether the bill adds protections or mainly restates existing requirements.